Ovid Therapeutics shares are trading lower after Takeda's Skyline study in Dravet syndrome missed its primary endpoint
Portfolio Pulse from Benzinga Newsdesk
Ovid Therapeutics shares are trading lower after Takeda's Skyline study in Dravet syndrome missed its primary endpoint.
June 17, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ovid Therapeutics shares are trading lower due to the failure of Takeda's Skyline study in Dravet syndrome to meet its primary endpoint.
The failure of Takeda's Skyline study in Dravet syndrome to meet its primary endpoint negatively impacts Ovid Therapeutics, likely causing a decline in investor confidence and a drop in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100